Volume 122, Issue 6 , Pages 1154-1160, December 2008
A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy
Background
Orally administered, food-specific immunotherapy appears effective in desensitizing and potentially permanently tolerizing allergic individuals.
Objective
We sought to determine whether milk oral immunotherapy (OIT) is safe and efficacious in desensitizing children with cow's milk allergy.
Methods
Twenty children were randomized to milk or placebo OIT (2:1 ratio). Dosing included 3 phases: the build-up day (initial dose, 0.4 mg of milk protein; final dose, 50 mg), daily doses with 8 weekly in-office dose increases to a maximum of 500 mg, and continued daily maintenance doses for 3 to 4 months. Double-blind, placebo-controlled food challenges; end-point titration skin prick tests; and milk protein serologic studies were performed before and after OIT.
Results
Nineteen patients, 6 to 17 years of age, completed treatment: 12 in the active group and 7 in the placebo group. One dropped out because of persistent eczema during dose escalation. Baseline median milk IgE levels in the active (n = 13) versus placebo (n = 7) groups were 34.8 kUa/L (range, 4.86–314 kUa/L) versus 14.6 kUa/L (range, 0.93–133.4 kUa/L). The median milk threshold dose in both groups was 40 mg at the baseline challenge. After OIT, the median cumulative dose inducing a reaction in the active treatment group was 5140 mg (range 2540-8140 mg), whereas all patients in the placebo group reacted at 40 mg (P = .0003). Among 2437 active OIT doses versus 1193 placebo doses, there were 1107 (45.4%) versus 134 (11.2%) total reactions, with local symptoms being most common. Milk-specific IgE levels did not change significantly in either group. Milk IgG levels increased significantly in the active treatment group, with a predominant milk IgG4 level increase.
Conclusions
Milk OIT appears to be efficacious in the treatment of cow's milk allergy. The side-effect profile appears acceptable but requires further study.
Key words: Cow's milk, food allergy, IgE, prognosis, desensitization, tolerance, oral immunotherapy
Abbreviations used: CM, Cow's milk, CMA, Cow's milk allergy, DBPCFC, Double-blind, placebo-controlled food challenge, OIT, Oral immunotherapy, SPT, Skin prick test
Supported by National Institutes of Health (NIH) training grant no. 5T32 AI07007, the Eudowood Foundation, NIH training grant no. 5T32AI007062-30, and Duke Clinical Research Unit/Clinical and Translational Science Award grant no. 5UL1-RR024128-02.
Disclosure of potential conflict of interest: A. W. Burks has consulting arrangements with ActoGeniX, NV, Novartis, McNeil Nutritionals, and Mead Johnson; owns stock in Allertein and MastCell, Inc; is on the advisory board for Dannon Co, Probiotics; is on the speakers' bureau for EpiPen/Dey; is on the data-monitoring committee for Genentech; is on an expert panel for Nutricia; has received research support from the National Institutes of Health (NIH), the Food Allergy and Anaphylaxis Network (FAAN), Gerber, and Mead Johnson; has served as an expert witness in food allergy litigation; and has served as a member of the FAAN, the American College of Allergy, Asthma & Immunology, the NIH, Hypersensitivity, Autoimmune, and Immune-mediated Diseases, and the Journal of Allergy and Clinical Immunology. R. A. Wood has received research support from Genentech and is on the advisory board for the FAAN and Dey. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)01725-9
doi:10.1016/j.jaci.2008.09.030
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 122, Issue 6 , Pages 1154-1160, December 2008
